Celecoxib

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

Celecoxib Chemical Structure

Molecular Weight(MW): 381.37

Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 26 Publications

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description Celecoxib is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.
Targets
COX-2 [1]
(Sf9 cells)
40 nM
In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. [1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 M2rLUmZ2dmO2aX;uJGF{e2G7 M2jye|AvOS1|MDFOwG0> NVfs[mtHPDhiaB?= MVrpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> M3uwdVI3PTF|MUey
H460 M2SyPGZ2dmO2aX;uJGF{e2G7 MYewMlEuOzBizszN NVWzZmFtPDhiaB?= MYrpcoR2[2W|IFnDRW0uOSCneIDy[ZN{cW:wIH;uJIJwfGhicILveIVqdiCjbnSgcXJPSSCuZY\lcC=> MlHMNlY2OTNzN{K=
HKESC-2 NFnCVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLUNlDDqM7:TR?= NEW3TFY1QMLiaNMg NIT0SZh{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW|IH;mJI95[WyrcHzheIlvyqB? Mk\VNlY1PzR4OUO=
CaES-17 M3H1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXDNlDDqM7:TR?= NXew[HNqPDkEoHlCpC=> MYrzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA> NHvDc2wzPjR5NE[5Ny=>
HKESC-2 NWHpcWtNSXCxcITvd4l{KEG|c3H5 MXeyNOKh|ryP Ml36OFjDqGkEoB?= NELIUpBz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NXfsNlM2OjZ2N{S2PVM>
CaES-17 NYH4TZVzSXCxcITvd4l{KEG|c3H5 NEPFemwzOMLizszN M3HjSlQ5yqCqwrC= NEfCbZJz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{ NVXRZ|B1OjZ2N{S2PVM>
A549 M{TCZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWG1MVE3OCEQvF2= NWnwXVlJPDkEoHlCpC=> MnfoSG1UVw>? NFXIeFhKSzVyPUG2N{41KM7:TR?= MWiyOlQ3PDZ2Mx?=
HCC827 NF;5VFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PrbFUuOTZyIN88US=> MmXHOFjDqGkEoB?= MonNSG1UVw>? NEf1T3lKSzVyPU[5MlIh|ryP MUiyOlQ3PDZ2Mx?=
A549 NHXaV5FCeG:ydH;zbZMhSXO|YYm= NXu0NIN6QDBiwsXN NEj5VmQ1QMLiaNMg MmHZSG1UVw>? Ml3mbY5lfWOnczDhdI9xfG:|aYO= Mlm5NlY1PjR4NEO=
HCC827 NH3s[JdCeG:ydH;zbZMhSXO|YYm= MUm4NEDDvU1? NEHLUXI1QMLiaNMg MXPEUXNQ NEPVfIRqdmS3Y3XzJIFxd3C2b4Ppdy=> MXyyOlQ3PDZ2Mx?=
SGC-7901/DDP M1jFemZ2dmO2aX;uJGF{e2G7 NFrvW44yOMLiwsXN MY[yOEBp Mk\EbY5pcWKrdIOgZ5lkdG:xeInn[Y5ie2VvMjDhcoQhWC2pbInjc5Bzd3SnaX6g[ZhxemW|c3nvci=> NInKPJgzPjRyN{[1Ny=>
SGC-7901  M1P0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\qSnQzPMLiaNMg M1zGc2lEPTB;MUG1MlA5KM7:TR?= MXWyOlQxPzZ3Mx?=
SGC-7901/DDP MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknWNlTDqGkEoB?= NHu3bVNKSzVyPUO1MlQ2KM7:TR?= MmnENlY1ODd4NUO=
SGC-7901/DDP M3jqPWFxd3C2b4Ppd{BCe3OjeR?= NEDBSG0yOMLiwsXN NHTifYUzPCCq MmHJbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCC5aYToJINqe3CuYYTpci=> NWXS[mxsOjZ2MEe2OVM>
SGC-7901/DDP MVnGeY5kfGmxbjDBd5NigQ>? NULOTpBpOTEEoNM1US=> MYGyOEBp M1z6bIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJHAu\2y7Y3;wdo91\WmwIITodo92\2hiYnzvZ4tqdmdiRWCyMEBidmRiaX7hZ5RqfmG2aX7nJHBMSSCjbnSgR3JGSsLi MUKyOlQxPzZ3Mx?=
SGC-7901/DDP MWLGeY5kfGmxbjDBd5NigQ>? MkS3NVDDqML3TR?= Moi4NlQhcA>? NF\sS5Jk[XW|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4> MnPXNlY1ODd4NUO=
H357 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\YWHB2Py53L{GwJO69VQ>? M3zl[lQ5KGh? MlnESG1UVw>? NXjrW4FEcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>? NYG2VJdUOjZyMEm4O|Q>
TAF MXrGeY5kfGmxbjDBd5NigQ>? NI\zbosyOMLiwsXN NFSzfZM4KGR? MkfPZYZn\WO2czDURWZ{KGGmaHXzbZZmKHC{b4DldpRq\XN? MWSyOVk5PzF{Nx?=
TAF MX7GeY5kfGmxbjDBd5NigQ>? MYGxNOKhyrWP MXqzNE0yOjBibXnu NYi5WI9{eG:xcnz5JIFn\mWldIOg[GFsfCCyaH;zdIhwenmuYYTpc44h[2:wc3XxeYVvfCC2bzDFS2Yhe2mpbnHsbY5o MV2yOVk5PzF{Nx?=
TAF MW\GeY5kfGmxbjDBd5NigQ>? NFrSc5EyOMLiwsXN M2PRT|Q5KGh? NGm3[ZZqdmO{ZXHz[ZMhTUeIUjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MnnDNlU6QDdzMke=
PANC-1 M1y2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3r0ZlIxNzZyL{GwNEDPxE1? MV6yOE81QC95MjDo MmjZbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MonCNlU6PzNyNkK=
PANC-1 NEH4d3hHfW6ldHnvckBCe3OjeR?= MlvnNlAwPjBxMUCwJO69VQ>? NF[2W|gzPCCq NIfRWmlifHSnboXheJMh[2WubDDpcpZie2mxbjDhcoQhdWmpcnH0bY9vKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MkTqNlU6PzNyNkK=
HeLa  NWnqOIRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITRSWozOMLizszNxsA> NHzTO4YzPMLiaB?= NWjZ[HdU\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36= NIXCbXAzPTd5MESyNy=>
SACC-83 NI\u[|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUiyNOKh|ryPwrC= MmTUNlTDqGh? MoPx[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? NFHmNngzPTd5MESyNy=>
HeLa  NVHw[JdvSXCxcITvd4l{KEG|c3H5 MVuyNOKh|ryPwrC= M2Lwb|I1yqCq M2jUXoVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBieG:ydH;zbZM> MWGyOVc4ODR{Mx?=
SACC-83 MnnZRZBweHSxc3nzJGF{e2G7 M3zG[lIxyqEQvF5CpC=> M{TuXVI1yqCq Mmry[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=> NUG4Xmd6OjV5N{C0NlM>
HeLa  NVzCV4FDTnWwY4Tpc44hSXO|YYm= Ml\GNlAwPDBxOECg{txO M2nFb|I1yqCq MXr1dJJm\3WuYYTzJHBVTU5icHHyeIlidGy7IHL5JIlvcGmkaYTpcochW3BzLDDhcoQh[WO2aY\heIV{KFCWRV6gZY5lKGmwYXP0bZZifGW|IFHLWC=> NYDPdpJZOjV5N{C0NlM>
SACC-83 MkD6SpVv[3Srb36gRZN{[Xl? NGnsVXczOC92MD:4NEDPxE1? NVqycGUyOjUEoHi= NGP3V2t2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>? MkLENlU4PzB2MkO=
HLCZ01 NVrab2tjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6wWmlKOOLCk{[wxsDDvU1? NETITG81QCCq MnjHSG1UVw>? NYTTfJhUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MYKyOVczPDh7OR?=
HLCZ01 MYTGeY5kfGmxbjDBd5NigQ>? M1L3b|QxyqEQvF2= M{P0bVI1KGh? NIHTfnlFVVOR NWPXeYVycW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>? MlTlNlU4OjR6OUm=
HLCZ01 M4LsVGFxd3C2b4Ppd{BCe3OjeR?= MX20NOKh|ryP NXu2fYhHOjRiaB?= MmXmSG1UVw>? NEjKeWpmdmijbnPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDJSm4u|rF? MoXpNlU4OjR6OUm=
HLCZ01 NUG0b4pZTnWwY4Tpc44hSXO|YYm= M{PodlQxyqEQvF2= M3LSWlI1KGh? MnTlSG1UVw>? NXy3dWZHcW6lcnXhd4V{KFSUQVnMJIV5eHKnc4Ppc44h[2:vYnnu[YQhf2m2aDDJcpRmem[ncn;uMe6y MXiyOVczPDh7OR?=
MGC803 M4nZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViwMVYxKM7:TR?= M4XJd|czKGh? MX\JR|UxRTR5LkK15qCKyrIkgJm2MlQ{KM7:TR?= MnPxNlU4ODF|N{i=
SGC7901 NHHFU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmwMVYxKM7:TR?= M3\Oc|czKGh? NHO0VJhKSzVyPUSzMlU{6oDLwsJihKk2NjF{IN88US=> MmLINlU4ODF|N{i=
MGC803 M{C5O2Z2dmO2aX;uJGF{e2G7 NGHUfGU1OMLizszN M4f5UVgwOTZxMkSgbC=> NUDrZWg4fXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NVf6enZROjV5MEGzO|g>
SGC7901 Mn7vSpVv[3Srb36gRZN{[Xl? Ml\ROFDDqM7:TR?= MU[4M|E3NzJ2IHi= NXzFe5FXfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v NWDz[5UzOjV5MEGzO|g>
MCF-7  Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vCVlEwOTBizszN M4HBV|czKGh? MWjEUXNQ NXW3OlVL\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36= MnjLNlU3Pjd3MUC=
MDA-MB-231  M2fDdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfUWHJPOS9zMDFOwG0> MlnwO|IhcA>? NHTKZmRFVVOR NEfifHpmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?= MknoNlU3Pjd3MUC=
MDA-MB-231 NEHCS2FHfW6ldHnvckBCe3OjeR?= MY[wMVQxKML3TR?= NHnMXmc1NTJ2IHi= M3fVO4lv[3KnYYPld{BEV1hvMjDwdo91\WmwIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MVWyOVU5PzN{OR?=
MCF-7 MVzGeY5kfGmxbjDBd5NigQ>? NUTJTYhqOC12MDFCuW0> NV7QTFFiPC1{NDDo MVjlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW|c3nvcuKh M1y5cVI2PTh5M{K5
MCF7-MX  NHzNeo5HfW6ldHnvckBCe3OjeR?= MmTtNE01OCEEtV2= NImzfXg1NTJ2IHi= NF7rb5VmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS|Ih\XiycnXzd4lwdsLi MV[yOVU5PzN{OR?=
MDA-MB-231 MWDGeY5kfGmxbjDBd5NigQ>? M4rEbFAuPDBiwsXN MV:0MVI1KGh? NEfXSpB{fGmvdXzheIV{KHSqZTDlfJBz\XO|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC= MUCyOVU5PzN{OR?=
A2780 M3XOcGZ2dmO2aX;uJGF{e2G7 MX61M|ExNzF3IN88US=> MUG0PEBp M333RYRm[3KnYYPld{BEd3hvMjDlfJBz\XO|aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M1:wS|I2PDJ2OEm4
SKOV3  MYrGeY5kfGmxbjDBd5NigQ>? NFPWTng2NzFyL{G1JO69VQ>? NETqflM1QCCq MmXu[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGrk[VMzPTR{NEi5PC=>
A2780 MmDhSpVv[3Srb36gRZN{[Xl? NXXoRm5mPS9zMD:xOUDPxE1? NXTjRZExPDhiaB?= MULlcIV3[XSnczD0bIUh\XiycnXzd4lwdiCxZjDFMYNi\GincnnuJIFv\CCtZYLheIlv Mk\2NlU1OjR6OUi=
SKOV3  NWHvepVnTnWwY4Tpc44hSXO|YYm= MV21M|ExNzF3IN88US=> Mn\tOFghcA>? NYLHd|RX\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?= NEPCVG8zPTR{NEi5PC=>
A2780 MY\GeY5kfGmxbjDBd5NigQ>? NYjYO4tIPS9zMD:xOUDPxE1? NGPGbGo1QCCq NXOycIxz\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu NI\sRowzPTR{NEi5PC=>
SKOV3  NV\jZnhxTnWwY4Tpc44hSXO|YYm= NHfwT|Q2NzFyL{G1JO69VQ>? NEe0V|c1QCCq NVXvO4pK\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKE5vY3HkbIVzcW5iYX7kJHZqdWWwdHnu MnLwNlU1OjR6OUi=
A2780 M3npT2Z2dmO2aX;uJGF{e2G7 NXjGVFVOPS9zMD:xOUDPxE1? Ml3INUBp NHvLPJpqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YheC2DS2SgZY5lKHBvRWLLJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MnPYNlU1OjR6OUi=
SKOV3  Mn;mSpVv[3Srb36gRZN{[Xl? NID6[WQ2NzFyL{G1JO69VQ>? MoDqNUBp MVHpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gdE1CU1RiYX7kJJAuTVKNIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmHENlU1OjR6OUi=
HCT-15 MkDnSpVv[3Srb36gRZN{[Xl? NELZT3kyOC13MDFOwG0> NX\hbIdGPi1|NjDo NVrle3o6cW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> MnzxNlUzOThyMki=
HT-29  M1XZPWZ2dmO2aX;uJGF{e2G7 NEjO[ZcyOC13MDFOwG0> NXzxO3FMPi1|NjDo MVXpcoR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NWDaUpBqOjV{MUiwNlg>
HSC3  NWHXSphDS2WubDDWbYFjcWyrdImgRZN{[Xl? M{DV[VDjiJN2MDFOwG0> NIm2[5k1QCCq NIXxeWpKSzVyPUK1MlXDuTFwN{iwJO69VQ>? M3vNSFI2OTl6N{i5
HSC3  NYD4TnZGSXCxcITvd4l{KEG|c3H5 NXPOeJp4OjVizszN NH3ZZ3c1QCCq M{\1d4lv\HWlZYOgZZBweHSxc3nz Ml\aNlUyQTh5OEm=
HSC3  MWTGeY5kfGmxbjDBd5NigQ>? NEjnV4czPSEQvF2= M2DRO|Q5KGh? NUXHPWRM\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?= MmPkNlUyQTh5OEm=
HSC3  NWX2boFMTnWwY4Tpc44hSXO|YYm= M4qxXVI2KM7:TR?= NUnvWVc5PDhiaB?= NX7TcJhMcW6qaXLpeJMhUFOFMzDj[YxtKGmwdnHzbY9vKGOxbXLpcoVlKHerdHigR2VV NFLudnIzPTF7OEe4PS=>
HSC3  MXLGeY5kfGmxbjDBd5NigQ>? Mli5NlUh|ryP M3nhNFczKGh? MkS3[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg NF;ycXkzPTF7OEe4PS=>
201T  NVr1[FZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\TfG44OiCq NF7XPGxFVVOR NHr1N5BKSzVyPUS4MlYhyrWP Mn;hNlUxPTd7NEG=
273T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLLWXU6PzJiaB?= MWTEUXNQ MXrJR|UxRThyLkWgxtVO M4XxdVI2ODV5OUSx
Hep-2 NVTjbZB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DXU|MxNzVyL{GwNEDPxE1? M1rERVEzNzJ2L{O2M|Q5KGh? MoLRSG1UVw>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWKyOFk6QDV4NB?=
Hep-2 NFK5SJNCeG:ydH;zbZMhSXO|YYm= MY[1NEDPxE1? NYf2RlRXOC12ODDo MXzEUXNQ M1nYVIlv\HWlZYOgZZBweHSxc3nzJIlvKGFidHnt[UBl\XCnbnTlcpQhdWGwbnXy M4XBWVI1QTl6NU[0
Hep-2 M2HG[GZ2dmO2aX;uJGF{e2G7 M{XCcVUxKM7:TR?= NXXYfWlpOC12ODDo NF7BXGVFVVOR M{fn[JJm\HWlZYOgeIhmKHSnbH;t[ZJie2ViYXP0bZZqfHliZ4Lh[JVidGy7 NILWRoMzPDl7OEW2OC=>
Hep-2 NIr1b5NHfW6ldHnvckBCe3OjeR?= Mni5OVAh|ryP NI\YUJQxNTR6IHi= NH3ZWWpFVVOR Mnf0[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ> M2TGb|I1QTl6NU[0
SGC-7901 NH3wUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2n1UVExNzVyL{GwNEDPxE1? MkDpNlQwPDhxN{KgbC=> NUTIUXpUTE2VTx?= MmGxbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NVjtUWJyOjR7OUK5OVg>
MKN-45 M2PwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYGxNE82OC9zMECg{txO MU[yOE81QC95MjDo NV;rSWFuTE2VTx?= M1u3eolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NELTRXozPDl7Mkm1PC=>
SGC-7901 M1TDTGZ2dmO2aX;uJGF{e2G7 M3rXcFExNzVyL{GwNEDPxE1? MorpOFghcA>? NFPvU5NFVVOR NIHabZFld3ewcnXneYxifGW|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NU[yZpB1OjR7OUK5OVg>
MKN-45 MkSzSpVv[3Srb36gRZN{[Xl? NGG5[JUyOC93MD:xNFAh|ryP MnTWOFghcA>? MXPEUXNQ NWjEWW9I\G:5boLl[5Vt[XSnczD0bIUhdVKQQTDlfJBz\XO|aX;uJIxmfmWuczDv[kBEV1hvMjDhcoQhWEOQQTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MVqyOFk6Ojl3OB?=
C666-1 NHroeoFEgXSxdH;4bYNqfHliQYPzZZk> MV[yNE05OCEQvF2= Mn\HNlQhcA>? NX7M[Fkz\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M13yflI1QDV2OEO4
CNE-1 NUe3TG9KS3m2b4TvfIlkcXS7IFHzd4F6 NEfLZ|czOC16MDFOwG0> M2jG[lI1KGh? NGnnO21l\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh NInwfo4zPDh3NEizPC=>
CNE-2 NX\iOYtIS3m2b4TvfIlkcXS7IFHzd4F6 MV2yNE05OCEQvF2= NHf2flQzPCCq MoO0[IVkemWjc3XzJINwdG:weTDmc5Ju[XSrb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYNCpC=> MoHiNlQ5PTR6M{i=
C666-1 MkHKR5l1d3SxeHnjbZR6KEG|c3H5 NIK2Wmk3OCEQvF2= NXW1R2lXPyCm MVLlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?= NIO4VoEzPDh3NEizPC=>
CNE-1 NUDnXWVmS3m2b4TvfIlkcXS7IFHzd4F6 M{LXU|YxKM7:TR?= MkDkO{Bl NYHFVZpq\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI> NIHEfGUzPDh3NEizPC=>
SNU-1041 M1e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP4NE01OCEQvF2= NXO4WmZtPDhiaB?= MV3pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlvkNlQ3QTJ5MEO=
SNU-1041 MlnoSpVv[3Srb36gRZN{[Xl? MWOyNE8{OCEQvF2= MmjQOEBp MmPtbY5lfWOnczDlfJBz\XO|aX;uJI9nyqCFSF;QMEBIWlB5ONMgZY5lyqC[QmCxxsBifCC2aHWgVm5CKGyndnXsxsA> MWGyOFY6OjdyMx?=
SNU-1041 MUjGeY5kfGmxbjDBd5NigQ>? M1Kwb|AuPDBizszN NV3LR4QyPCCq NVrrSFR1fXBvcnXneYxifGW|IFPIU3DDqGGodHXyJJRz\WG2bXXueEB4cXSqIHjp[4gh[2:wY3XueJJifGmxboO= MY[yOFY6OjdyMx?=
SGC-7901 M3fCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[2NHI2OC1zMkWg{txO NEL6RYYzPC92OD:3NkBp MV;pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MUKyOFY4PjN7NB?=
SGC-7901 NEfFeFJCeG:ydH;zbZMhSXO|YYm= NVjwdHFJOTByIN88US=> M160[|czKGh? Mn\EbY5lfWOnczDhdI9xfG:|aYO= NUWwdGoxOjR4N{[zPVQ>
SGC-7901 MWHGeY5kfGmxbjDBd5NigQ>? MWO3OU8yODBxMUK1JO69VQ>? MWKyOE81QC95MjDo MkfsbY5kemWjc3XzJINie3Cjc3WtPEBidmRiLUmgcXJPSSCneIDy[ZN{cW:wIHnuJIJwfGhidHnt[UBidmRiZH;z[UBu[W6wZYK= NY[4ZVl6OjR4N{[zPVQ>
LMeC  MUXGeY5kfGmxbjDBd5NigQ>? NW\RV5dUOjBxNUCg{txO NEnQbG41QCCq M4PkWYRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw M1Hjc|I1PjV4N{S2
CMeC-1 NFz6epdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGLTW2szOC93MDFOwG0> MXm0PEBp NF;vU3JqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1S1OVI1PjV4N{S2
LMeC MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4jiU|IxNzVyIN88US=> M3TMNFQ5KGh? NWXZb49ucW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MlfpNlQ3PTZ5NE[=
CMeC-1 MWjGeY5kfGmxbjDBd5NigQ>? NHTFT24zOC93MDFOwG0> M4D2[lQ5KGh? NVjEZZU5cW6mdXPld{BIOS2VIHHydoV{fA>? NHr2[5EzPDZ3Nke0Oi=>
LMeC NHf0VIZHfW6ldHnvckBCe3OjeR?= NFzhV3UzOC93MDFOwG0> NH;kcGg1QCCq MYHpcoR2[2W|IFexMXMh[XK{ZYP0 NXT4VGJIOjR4NU[3OFY>
CMeC-1 M3fue2Z2dmO2aX;uJGF{e2G7 M4HLOVIxNzVyIN88US=> NFXHe5M1QCCq NUPBb4s{\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gZ5lkdGmwIFSxJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUfhVWx[OjR4NU[3OFY>
LMeC M2XRO2Z2dmO2aX;uJGF{e2G7 NIjCPGszOC93MDFOwG0> MVW0PEBp M3\0eYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NHuzNpozPDZ3Nke0Oi=>
CMeC-1 MWHGeY5kfGmxbjDBd5NigQ>? M13GfVIxNzVyIN88US=> NWXTdXV[PDhiaB?= Mn[2bY5lfWOnczDjZZNx[XOnLUOgZYN1cX[jdHnvci=> M3q1O|I1PjV4N{S2
LMeC NFziVFlHfW6ldHnvckBCe3OjeR?= NFHjUXczOC93MDFOwG0> NFz0RnU1QCCq NVXQSHRLcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>? NXHTb3RVOjR4NU[3OFY>
OVCAR-3 NIjENmtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFX3R4QyOCEEtV2= M3vhc|EhcA>? Mn3Q[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJI93[XKrYX6gZ4Fv[2W{IHPlcIwh\GWjdHlCpC=> M4LQRlI1PTJyMkK3
OVCAR-3 MWPBdI9xfG:|aYOgRZN{[Xl? NWPVXnFXOTBiwsXN MnHVNUBp M3TrUpBzd22xdHXzJJBi[2yrdHH4[YwucW6mdXPl[EBieG:ydH;zbZPDqA>? MkHhNlQ2OjB{Mke=
OVCAR-3 NHLHRYlHfW6ldHnvckBCe3OjeR?= NV3qZW5bOTBiwsXN Mk\2NUBp M1mzcoVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBi[3SrdnH0bY9vKG:oIHPhd5Bie2VvOdMg M{n6eFI1PTJyMkK3
OVCAR-3 M2G2VWZ2dmO2aX;uJGF{e2G7 NWfDO2JyOTBiwsXN NX3wZ|k5OSCq M{C5XoRwf25vcnXneYxifGW|IF7GMe67SiCjY4TpeoF1cW:wIHnu[JVk\WRiYomgdIFkdGm2YYjlcC=> M2T0SFI1PTJyMkK3
OVCAR-3 NF3lSZFHfW6ldHnvckBCe3OjeR?= NX3W[mV3OTBiwsXN M1LkR|EhcA>? MkG1bY5pcWKrdIOgdIFkdGm2YYjlcE1qdmS3Y3XkJGFsfCCyaH;zdIhwenmuYYTpc44> NHTV[o8zPDV{MEKyOy=>
CF33 MX\GeY5kfGmxbjDBd5NigQ>? MU[xNFAh|ryP M2LTO|I1KGh? NHX4d2dqdmS3Y3XzJIRwf26{ZXf1cIF1cW:wIH;mJGNQYC1{IIDyc5RmcW5iZYjwdoV{e2mxbh?= NHu4flMzPDVyM{e4Ni=>
CF33 MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjyNVAuOTByIN88US=> MVWwMVQh\A>? NYm3[lVkcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4PRPVI1PTB|N{iy
CF33 MmLmSpVv[3Srb36gRZN{[Xl? MW[xNE0yODBizszN NVO3T4tQPC1{NDDo M2XNN4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy|IHnuJGcxN0dzIHHydoV{fA>? MlzkNlQ2ODN5OEK=
LNCaP Moq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU[yM|UwOTBizszN Ml;zPVYhcA>? NGnseG1qdmirYnn0d{Bk\WyuIHfyc5d1cCC|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu MYCyOFI6Pjl5OB?=
LNCaP NV61bGFlSXCxcITvd4l{KEG|c3H5 MorUNk82NzFyIN88US=> MlnUPVYhcA>? MlzpbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCjdH;yeoF{fGG2aX6= NX3DUVl3OjR{OU[5O|g>
PC-3  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPJe5UxNTVyIN88US=> M4HSUFQ56oDLaB?= M{DNcIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MkHXNlQyOjd6OEK=
PC-3  MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX\ITphtOC1zMECg{txO MnS3O|IhcA>? Mnru[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ NFz3Z3EzPDF{N{i4Ni=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Fibronectin / Vimentin / N-cadherin / E-cadherin ; 

PubMed: 28978083     


(A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells.

COX-2; 

PubMed: 29515134     


L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. 

pAKT / AKT / PPARγ / PTEN ; 

PubMed: 24721996     


Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h. 

28978083 29515134 24721996
Immunofluorescence
PPARγ / PTEN ; 

PubMed: 24721996     


Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.

24721996
Growth inhibition assay
Cell viability; 

PubMed: 28521485     


Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth. 

28521485
In vivo Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. [1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). [3]

Protocol

Kinase Assay:[1]
- Collapse

COX enzyme assay in vitro:

Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:[2]
- Collapse
  • Cell lines: HNE1 and CNE1-LMP1
  • Concentrations: 0-75 μM
  • Incubation Time: 48 hours
  • Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats.
  • Formulation: Celecoxib is dissolved in 0.5% methyl cellulose and 0.025% Tween-20.
  • Dosages: ≤200 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 76 mg/mL (199.28 mM)
Ethanol 33 mg/mL (86.53 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 381.37
Formula

C17H14F3N3O2S

CAS No. 169590-42-5
Storage powder
in solvent
Synonyms SC 58635

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03896113 Not yet recruiting Drug: Celecoxib 200mg capsule Endometrium Cancer Cliniques universitaires Saint-Luc- Université Catholique de Louvain June 30 2019 Phase 2
NCT03643744 Recruiting Drug: Celecoxib 200mg|Drug: Placebo Actinic Keratosis|Photodynamic Therapy Jeffrey B. Travers MD PhD|Wright State Physicians April 1 2019 Phase 1
NCT01344200 Not yet recruiting Drug: Celecoxib Pharmacokinetics of Celecoxib in Children Children''s Hospital of Eastern Ontario March 2019 Phase 4
NCT02876094 Recruiting Drug: celecoxib Spinal Muscular Atrophy (SMA) Hugh McMillan|Families of Spinal Muscular Atrophy|Gwendolyn Strong Foundation|Children''s Hospital of Eastern Ontario January 29 2019 Phase 2
NCT03672162 Recruiting Procedure: Total abdominal hysterectomy Total Abdominal Hysterectomy Pain Acute PostoperativeGabapentin Celecoxib Rajavithi Hospital September 1 2018 Not Applicable
NCT03541655 Active not recruiting Drug: Bupivacaine HCl|Drug: F14 (celecoxib) Total Knee Replacement|Postoperative Pain Arthritis Innovation Corporation May 4 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?

  • Answer:

    For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Related COX Products

Tags: buy Celecoxib | Celecoxib supplier | purchase Celecoxib | Celecoxib cost | Celecoxib manufacturer | order Celecoxib | Celecoxib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID